Table 2.

Safety profile across key phase III trials of first-line chemotherapy with or without immunotherapy

Trial	Any grade TRAEs (%)	G3-4 TRAEs (%)	TRAEs leading to treatment discontinuation (%)	Most common G3-4 TRAEs	G5 TRAEs
ABC-028	NR	70.7	10.5	Decreased neutrophil count, fatigue, infections	NR
TOPAZ-128,29	93.0	61.0	9.0	Decreased neutrophil count, anemia, neutropenia	2
KEYNOTE-96634	93.0	70.0	19.0 (discontinued one or more study drugs)	Decreased neutrophil count, anemia, decreased platelet count	9
			3.0 (discontinued all study drugs)

TRAE, treatment-related adverse event; G, grade; NR, not reported.